ATM and colorectal carcinoma: Because of the consistent prevalence of ATM mutations in CRC (7% in non-hypermutated cases)14 and their potential crucial role as biomarker of chemosensitivity to platinum salts and topoisomerase inhibitors, ATM mutations would therefore characterize mCRC patients with a more favourable outcome, at least when eligible for combination chemotherapy.